Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

gy. It is a small- molecule inhibitor of lipoprotein-associated phospholipase-A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques and identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK is developing darapladib as a treatment for atherosclerosis, and it has the potential to be an important treatment for the prevention of cardiovascular risk. HGS will receive a 10% royalty on worldwide sales if darapladib is commercialized, and also has a co-promotion option in North America and Europe, under which it would pay 20% of commercialization costs in exchange for 20% of darapladib profits. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance darapladib to Phase 3 development.

Syncria(R): 2008 Phase 3 Decision Possible

In May 2007, GSK initiated a randomized Phase 2b dose-ranging clinical trial of Syncria (albiglutide) in patients with type 2 diabetes. As a comparison, one group of patients is receiving Byetta (exenatide).

Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology. Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood sugar levels and to control appetite. GSK is developing Syncria as a treatment for type 2 diabetes mellitus. HGS is entitled to fees and milestone payments, some of which have already been received, that could amount to as much as $183 million, in addition to royalties on worldwide sales if Syncria is commercialized. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance Syncria to Phase 3 development.

HGS-XENCOR ANTIBODY COLLABORATION

On February 7, 2008, HGS and Xencor, Inc. announced a collaboration agreement under which Xencor will apply its proprietary technologies
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LEXINGTON, Ky. , Sept. 18, 2014  Neogen ... it has entered into a strategic agreement with Merck ... Heifer Program. The Igenity Dairy Heifer ... producers essential information on the genetic potential of replacement ... after a calf is born, and is an excellent ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... new microscopy technology that allows them to view ... , Dubbed "Complementation Activated Light Microscopy" (CALM), the ... order of magnitude finer than conventional optical microscopy, ... at the nanometer scale. , In a paper ... , the researchers behind CALM used it to ...
Breaking Biology Technology:Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... have an intriguing ball-shaped structure that suggests several interesting ... that the passage of electrons through a bucky ball ... the ball around its center of mass. Moreover, since ... been thought that they may be useful as lubricants ...
... Oct. 16 NxStage Medical,Inc. (Nasdaq: NXTM ), ... release its financial results for the third,quarter 2007 on ... markets. NxStage will also host a conference call ... discuss its third quarter 2007 financial results. To,listen to ...
... Joins EntreMed,s Senior Management Team, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... W. Bair, Ph.D. has been appointed its Senior ... been elected an,executive officer of EntreMed by the ...
Cached Biology Technology:Bouncing bucky balls 2NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... millions of Americans to undertake jaunts into the countryside each ... longer within a century, according to new research. , Climate ... the United States as summer temperatures linger later into the ... Ecology and Biogeography . For instance, the paper birch ... New Hampshire could change color one to three weeks ...
(Date:9/18/2014)... the first smartphone app that automatically reveals students, ... other words, your smartphone knows your state of ... how that affects you. , The StudentLife app, ... to their academic performance, also may be used ... monitor mental health, trigger intervention and improve productivity ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... of information is a basic property of biological systems. ... impulses. Transmission of signals occurs at an ... signaling molecules, which bear a phosphate or a sulfate ... processes are of supreme importance, they have been extensively ...
... given six scientists more freedom to do especially innovative ... be awarded funding under the DFG,s Reinhart Koselleck Projects ... between 500,000 euros and 1.25 million euros for their ... use flexibly over a five-year period. The ...
... 2008)-Baruch Barry Lieber, Ph.D., professor of biomedical engineering at ... of radiology at the University of Miami Miller School ... Institute of Neurological Disorders and Stroke (NINDS), to support ... brain aneurysms., The $1.9 million grant administered over a ...
Cached Biology News:Sulfurous ping-pong in the urinary tract 2Sulfurous ping-pong in the urinary tract 3More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 2More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 3More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 4University of Miami biomedical engineer 2